Kirkland & Ellis’ M&A conflicts crisis deepened on Tuesday, when a federal magistrate judge in Pittsburgh recommended that the firm be barred from advising Israel’s Teva Pharmaceutical Industries Ltd in its $40 billion hostile bid for Mylan NV.

But Kirkland’s loss is Sullivan & Cromwell’s gain, as Teva announced that S&C will step in to advise the company in the cross-border takeover fight.